Fed. Circ. Slams Fee-Shifting Requirement In Pfizer IP Suit
The Federal Circuit on Monday ruled that a California federal court exceeded its discretion when it required biotech firm AntiCancer Inc. to pay the attorney fees of defendants Pfizer Inc. and...To view the full article, register now.
Already a subscriber? Click here to view full article